CNS PHARMACEUTICALS, INC.

2100 WEST LOOP SOUTH

SUITE 900

HOUSTON TX 77027

October 2, 2020

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

Re:	CNS Pharmaceuticals, Inc.
	Registration Statement on Form S-1
	Registration No. 333-249068

Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30 P.M. (Eastern Time) on October 6, 2020, or as soon thereafter as possible on such date.

Very truly yours,

CNS Pharmaceuticals, Inc.

By: /s/ Christopher Downs                                  

Name: Christopher Downs

Title: Chief Financial Officer